The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
Open accessAbstract
BACKGROUND ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. METHODS This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18-75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (2:1; stratified by previous exacerbation count [two, or three or more], maintenance oral corticosteroid use, and region), using an integrated web-based response system, to receive benralizumab at 30 mg every 8 weeks (first three doses given 4 weeks apart) or matched placebo for 24 weeks. Primary efficacy measure was annualised asthma exacerbation rate, with rate ratio (RR) calculated over the approximate 24-week follow-up. Secondary efficacy measures included change from baseline to end of treatment (week 24) in St George's Respiratory Questionnaire (SGRQ) total score (key secondary endpoint), FEV1, peak expiratory flow (PEF), ACQ-6, Predominant Symptom and Impairment Assessment (PSIA), Clinician Global Impression of Change (CGI-C), Patient Global Impression of Change (PGI-C), and Sino-Nasal Outcome Test-22 (SNOT-22). All efficacy analyses, except for SNOT-22, were summarised and analysed using the full analysis set on an intention-to-treat population (all randomly assigned patients receiving investigational product, regardless of protocol adherence or continued participation in the study). SNOT-22 was summarised for the subgroup of patients with physician-diagnosed nasal polyposis with informed consent. This study is registered with ClinicalTrials.gov, NCT03170271. FINDINGS Between July 7, 2017, and Sept 25, 2019, 656 patients received benralizumab (n=427) or placebo (n=229). Baseline characteristics were consistent with severe eosinophilic asthma. Benralizumab significantly reduced exacerbation risk by 49% compared with placebo (RR estimate 0·51, 95% CI 0·39-0·65; p≤0·0001) over the 24-week treatment period and provided clinically meaningful and statistically significant improvement from baseline to week 24 in SGRQ total score versus placebo (least squares mean change from baseline -8·11 (95% CI -11·41 to -4·82; p≤0·0001), with similar differences at earlier timepoints. Benralizumab improved FEV1, PEF, ACQ-6, CGI-C, PGI-C, PSIA, and SNOT-22 at week 24 versus placebo, with differences observed early (within weeks 1 to 4). Adverse events were reported for 271 (63%) of 427 patients on benralizumab versus 143 (62%) of 229 patients on placebo. The most commonly reported adverse events for the 427 patients receiving benralizumab (frequency >5%) were nasopharyngitis (30 [7%]), headache (37 [9%]), sinusitis (28 [7%]), bronchitis (22 [5%]), and pyrexia (26 [6%]). Fewer serious adverse events were reported for benralizumab (23 [5%]) versus placebo (25 [11%]), and the only common serious adverse event (experienced by >1% of patients) was worsening of asthma, which was reported for nine (2%) patients in the benralizumab group and nine (4%) patients in the placebo group. INTERPRETATION Our results extend the efficacy profile of benralizumab for patients with severe eosinophilic asthma, showing early clinical benefits in patient-reported outcomes, HRQOL, lung function, and nasal polyposis symptoms. FUNDING AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationFokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Global asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521
Cited by
Biologic Therapies for Severe Asthma
Brusselle, G. G., & Koppelman, G. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032506 · Cited by 715
Bachert, C., Han, J. K., Desrosiers, M. Y., Gevaert, P., Heffler, E., Hopkins, C., Tversky, J. R., Barker, P., Cohen, D., Emson, C., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.030 · Cited by 336
Biologics and airway remodeling in severe asthma
Varricchi, G., Ferri, S., Pepys, J., Poto, R., Spadaro, G., Nappi, E., Paoletti, G., Virchow, J. C., Heffler, E., & Canonica, W. G. (2022) · Allergy · doi:10.1111/all.15473 · Cited by 254
Self-citationBreaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments
Li, G., Wan, Y., Jiao, A., Jiang, K., Cui, G., Tang, J., Yu, S., Hu, Z., Zhao, S., Yi, Z., et al. (2025) · Med Research · doi:10.1002/mdr2.70007 · Cited by 63
Metadata
- Authors
- Harrison, T. W., Chanez, P., Menzella, F., Canonica, G. W., Louis, R., Cosio, B. G., Lugogo, N. L., Mohan, A., Burden, A., McDermott, L., Garcia Gil, E., Zangrilli, J. G., Pohl, W., Voves, R., Deschampheleire, M., Louis, R., Martinot, J.-B., Peché, R., Chapman, K., Cheema, A., Dorscheid, D., FitzGerald, J. M., Gagnon, R., Killorn, W. P., Olivenstein, R., Philteos, G., Ramsey, C., Rolf, J. D., Walker, B., Hilberg, O., Skjold, T., Titlestad, I., Hakulinen, A., Kilpeläinen, M., Ben Hayoun, M., Bonniaud, P., Bourdin, A., Chanez, P., De Blay, F., Deslee, G., Devouassoux, G., Didier, A., Douadi, Y., Fry, S., Garcia, G., Girodet, P.-O., Leroyer, C., Magnan, A., Mahay, G., Nocent, C., Pison, C., Roux, P.-M., Taillé, C., Tiotiu, J.-A., Beck, E., Jandl, M., Kaehler, C., Kässner, F., Koesters, F., Kronsbein, J., Schaum, T., Schulz, C., Skowasch, D., Taube, C., Welte, T., de Roux, A., Beghé, B., Blasi, F., Canonica, G. W., Carpagnano, G., Caruso, C., Corsico, A. G., Constantino, E., Crimi, N., Maestrelli, P., Menzella, F., Milanese, M., Papi, A., Pelaia, G., Pini, L., Santus, P., Savi, E., Scichilone, N., Senna, G., Spadaro, G., Vaghi, A., Gans, S., Hölters, J., Langeveld, B., Pieters, W., Staaks, G. H. A., van Veen, I., van den Berg, J. W. K., Einvik, G., Lehmann, S., Ali García, I., Almonacid, C., Bobolea, I., Campo Mozo, P., de Luiz, G., Domingo Ribas, C., Echave-Sustaeta María-Tomé, J. M., García Rivero, J. L., García-Cosío Piqueras, B., Gómez-Bastero Fernández, A., González Pérez, R., Henríquez Santa, A., Martínez Rivera, C., Muñoz Gall, X., Ramos, J., Gregorio Soto Campos, J., Vidal Pan, C., Stenfors, N., Tunsäter, A., Vinge, I., Chaudhuri, R., Harrison, T., Mansur, A., Nasser, S., Nordstrom, M., Pfeffer, P., Saralaya, D., Short, P., Adlakha, A., Alpan, O., Averill, F., Badhwar, A., Bardelas, J., Baxter, B., Bensch, G., Berger, W., Bernstein, J., Bridges, T., Brimeyer, R., Calhoun, W., Campbell, E., Cherry, W. B., Chupp, G., Clore, L., Cohn, J., Cole, J., Condemi, J., Cury, J., Davis, B., DeLeon, S., Delacruz, L., Diaz, J., Erb, D., Eziri, E., Fakih, F., Fiedler, D., Fost, D., Fritz, S., Gonzalez, E., Goodman, B., Gottlieb, P., Gottschlich, G., Gower, R., Hajal, R., Harris, J., Heidarian-Raissy, H., Heyder, A., Hill, D., Holguin, F., Hussain, I., Illowite, J., Jacobs, J., Jarratt, M., Kaiser, H., Kao, N., Kashyap, R., Kaufman, D., Kent, E., Kim, K., Klein, R., Kraft, M., Kono, R., Kureishy, S., Leflein, J., Leong, M., Li, H., Lin, R., Lugogo, N., Marcus, M., Maselli Caceres, D. J., Mehta, V., Mello, C., Millard, M., Milstone, A., Mohan, A., Moore, W., Moss, M., Mumneh, N., O'Brien, T., Ostransky, D., Palumbo, M., Parikh, P., Parikh, S., Patel, A., Perez, G., Pleskow, W., Prenner, B., Puppala, D., Ramey, J., Reibman, J., Reyes, R., Robinette, E., Rodicio, I., Ryan, S., Sekhsaria, S., Sigal, B., Sikand, V., Soong, W., Spangenthal, S., St. John, R., Steven, G., Subramaniam, V., Sumino, K., Sztejman, E., Tan, R. A., Tanus, T., Thompson, C., Thornblade, C., Villareal, M., Wenzel, S., Zafra, H., & Ziedalski, T.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 9
- Issue
- 3
- Pages
- 260-274
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W3114098409
- Cited by
- 175
- References
- 3
- FWCI
- 12.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. https://app.cochat.ai/papers/10.1016/s2213-2600(20)30414-8
- The paper
- Harrison, T. W., Chanez, P., Menzella, F., Canonica, G. W., Louis, R., Cosio, B. G., Lugogo, N. L., Mohan, A., Burden, A., McDermott, L., Garcia Gil, E., Zangrilli, J. G., Pohl, W., Voves, R., Deschampheleire, M., Louis, R., Martinot, J.-B., Peché, R., Chapman, K., . . . Ziedalski, T. (2021). Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(20)30414-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.